...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Hepalink IPO Document and what it says about RVX

KOO - it appears from the HL doc that a Ph3 trial on the effect of ABL on CKD might be on the cards, suggesting CKD might be the basis of a BT designation.

Why the need for another trial if eGFR was increased in BETonMACE? Because eGFR is an estimate of true GFR based on serum creatinine, and as such might not be accepted by the FDA as proof of a beneficial effect. They might be asking for a new trial that specifically looks at true GFR (not eGFR) which is a little more complicated technically.

 

Share
New Message
Please login to post a reply